Role of galectin 3 and thyroid peroxidase as diagnostic tool in thyroid carcinoma with clinicopathological correlation: a cohort study of 94 cases
Keywords:Galectin 3, Thyroid peroxidase antibodies, Thyroid neoplasms
Background: Thyroid neoplasms constitute the most commonly occurring endocrine tumors worldwide. With ultrasonography, detection has been increased up to 30%. Thyroid neoplasms have a wide spectrum of clinical behaviour and varied therapeutic responsiveness. Thus, early diagnosis of thyroid tumors and appropriate management will prolong the survival rate of patients. So, this study focuses on thyroid tumors which have overlapping morphological features and exact diagnosis is essential for surgical and post- operative management of patients. The aim and objective of the study was to determine the role of Galectin 3 and Thyroid Peroxidase in malignant tumors of thyroid as diagnostic marker.
Methods: We evaluated the patients for detailed history, physical examination, fine needle aspiration cytology (FNAC) and biopsy or excision of thyroid gland and subsequently histological examination and Immunohistochemistry for galectin 3 and thyroid peroxidase antibody (TPO).
Results: A total of 94 cases were enrolled in the study. Out of these 94 cases, 70 cases (74%) were followed by histopathology and immunohistochemistry (IHC). Out of 70 cases, benign were 44 (63%) and malignant were 26 (37%). Among benign cases, most common were colloid goitre, 22 cases (31%). Among malignant cases, most common were papillary carcinoma, 15 cases (21%). For all thyroid carcinoma, both Galectin 3 and TPO showed sensitivity of 81% when used alone. However combination of galectin 3 and TPO increased the sensitivity up to 92%.
Conclusions: Galectin 3 and TPO alone has high sensitivity for all thyroid carcinoma but sensitivity was markedly increased when combination of the two markers were used.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
Gasbarri A, Marchetti C, Iervasi G. From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomed Pharmacother. 2004;58:356-35.
Hegedus L, Perrild H, Poulsen L. The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects. J Clin Endocrinol Metab. 1983;56:260-3.
Gupta M, Gupta S, Gupta VB. Correlation of Fine Needle Aspiration Cytology with Histopathology in the Diagnosis of Solitary Thyroid Nodule. Journal of Thyroid Research. 2010;379051.
Peng XG, Chen ZF, Zhang KJ, Wang PG, Liu ZM, Chen ZJ, et al. Vegf trapon inhibits tumor growth in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2015;19(2):235-40.
Fassina AS, Montesco MC, Ninfo V. Histological evaluation of thyroid carcinomas: reproducibility of the WHO classification. Tumori. 1993;79:314-20.
Saxen E, Franssila K, Bjarnason O. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand. 1978;86A:483-6.
Franc B, De La Salmoniere P, Lange F. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol. 2003;34:1092-100.
Hirokawa M, Carney JA, Goellner JR. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2002;26:1508-14.
Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The Use of a Combination of Galectin-3 and Thyroid Peroxidase for the Diagnosis and Prognosis of Thyroid Cancer. American Journal of Clinical Pathology. 2004;122(4):524-31.
Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Human pathology. 2008;39(11):1656-63.
David K, Marie L, Kholova I, Jaroslav L, Ondrej T, Plzák. Combined use of Galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors. Neoplasma. 2019;67:10.4149.
Pandav CS, Yadav K, Srivastava R, Pandav R, Karmarkar MG. Iodine deficiency disorders (IDD) control in India. Indian J Med Res. 2013;138(3):418-33.